A blood test from Guardant Health that reads tumour DNA in the bloodstream to find out whether certain targeted drugs for lung, breast or bowel cancer may work.
Guardant360 Liquid CDx is a separate FDA premarket approval (P250027, approved 19 May 2026 on an application received 31 July 2025) from the older Guardant360 CDx (P200010). The approval order describes a qualitative sequencing test on circulating cell-free DNA covering 741 genes for small variants. The FDA companion diagnostic list carries seven claims for it: osimertinib (EGFR exon 19 deletions, L858R and T790M), amivantamab (EGFR exon 20 insertions), sotorasib (KRAS G12C) and trastuzumab deruxtecan (ERBB2/HER2 activating mutations) in non-small cell lung cancer; elacestrant and imlunestrant (ESR1 mutations) in breast cancer; and encorafenib with cetuximab (BRAF V600E) in colorectal cancer. The approval order states that a negative plasma result does not assure that the tumour is negative, and that patients negative for the listed biomarkers should be reflexed to tissue testing with an FDA-approved tissue test where feasible. For osimertinib it adds that efficacy has not been established in the T790M plasma-positive, tissue-negative or unknown population.
Hybrid-capture next-generation sequencing of cell-free DNA from plasma, collected in Streck Cell-Free DNA Blood Collection Tubes, detecting single nucleotide variants and small insertions and deletions in 741 genes, copy number amplifications in two genes, copy number loss in one gene and rearrangements in nine genes. Connects to EGFR, KRAS, BRAF, Estrogen receptor (ERα) and HER2.
| Where | Who pays | Help with the cost | |
|---|---|---|---|
| 🇺🇸 United States | Approved 2026 | - | - |
Approval is the regulator's decision for any cancer indication, with the year of the first; it is not a promise that a hospital stocks the drug or that your indication is covered. Not recorded for European Union, United Kingdom, Japan, China, Australia, India: a gap in our research, not a refusal. Compare products across regions.
| Region | Year | Indication |
|---|---|---|
| US | 2026 | Companion diagnostic (plasma) for osimertinib, amivantamab, sotorasib and trastuzumab deruxtecan in NSCLC, elacestrant and imlunestrant in breast cancer, and encorafenib in colorectal cancer; also tumour mutation profiling in solid tumours |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Guardant360 Liquid CDx" OR ABSTRACT:"Guardant360 Liquid CDx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Guardant360 Liquid CDx, not a curated reading list.
Shares EGFR T790M, EGFR L858R, EGFR exon 19 deletion, Guardant360 CDx and the tag test.
Shares EGFR exon 20 insertion, HER2 (ERBB2) activating mutation, EGFR exon 19 deletion, BRAF V600E (and V600K) and the tag test.
Shares EGFR exon 19 deletion, KRAS G12C, BRAF V600E (and V600K), Companion diagnostic and the tag test.
Shares EGFR L858R, EGFR exon 19 deletion, Companion diagnostic, Companion diagnostics and the tag test.
Shares EGFR exon 20 insertion, HER2 (ERBB2) activating mutation, EGFR L858R, EGFR exon 19 deletion and the tag test.
Shares EGFR exon 20 insertion, ESR1 mutation (ligand-binding domain, usually in ctDNA), HER2 (ERBB2) activating mutation, EGFR L858R and the tag test.
Shares KRAS G12C, Companion diagnostics, Circulating tumour DNA (ctDNA), KRAS and the tag test.
Shares EGFR exon 19 deletion, KRAS G12C, BRAF V600E (and V600K), Companion diagnostics and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/